FindTrial
Sign In

Omegaven® (fish oil triglycerides) Injectable Emulsion

DRUG2 trials

Sponsors

Fresenius Kabi

Conditions

Essential Fatty Acid DeficiencyMalnutritionNeurocognitive DeficitParenteral Nutrition Associated Liver DiseaseParenteral Nutrition Associated Liver Disease (PNALD)Pediatric ALL

Unknown Phase

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
WithdrawnNCT04807478
Fresenius KabiEssential Fatty Acid Deficiency, Malnutrition, Neurocognitive Deficit +2
Start: 2022-04-01End: 2029-05-01Updated: 2022-08-04
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
RecruitingNCT06274788
Fresenius KabiEssential Fatty Acid Deficiency, Malnutrition, Parenteral Nutrition Associated Liver Disease (PNALD) +1
Start: 2024-12-15End: 2028-04-01Target: 40Updated: 2026-08-14